First-in-Human Phase 1 study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors.
El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, Kohlhas L, Vanosmael D, Koch J, Rajkovic E, Ravenstijn P, Nuciforo P, Fehniger TA, Foster M, Berrien-Elliott MM, Wingert S, Stäble S, Morales-Espinosa D, Rivas D, Emig M, Lopez J.
El-Khoueiry A, et al. Among authors: koch j.
Clin Cancer Res. 2025 Jan 23. doi: 10.1158/1078-0432.CCR-24-1991. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39846810